HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.
- Published in:
- NPJ Precision Oncology, 2025, v. 9, n. 1, p. 1, doi. 10.1038/s41698-025-00949-y
- By:
- Publication type:
- Article
Works by Du, Qingwu
Results: 12
1
2
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1128443
- By:
- Publication type:
- Article
3
Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-023-11646-z
- By:
- Publication type:
- Article
4
Correction: Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
5
Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10803-8
- By:
- Publication type:
- Article
6
Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11206-5
- By:
- Publication type:
- Article
7
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer (Adv. Sci. 14/2025).
- Published in:
- Advanced Science, 2025, v. 12, n. 14, p. 1, doi. 10.1002/advs.202570096
- By:
- Publication type:
- Article
8
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer.
- Published in:
- Advanced Science, 2025, v. 12, n. 14, p. 1, doi. 10.1002/advs.202413445
- By:
- Publication type:
- Article
9
Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial.
- Published in:
- Precision Radiation Oncology, 2020, v. 4, n. 4, p. 113, doi. 10.1002/pro6.1105
- By:
- Publication type:
- Article
10
A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.703074
- By:
- Publication type:
- Article
11
Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 18, p. 16365, doi. 10.1007/s00432-023-05371-0
- By:
- Publication type:
- Article
12
Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
- Published in:
- Journal of Leukocyte Biology, 2023, v. 113, n. 1, p. 11, doi. 10.1093/jleuko/qiac018
- By:
- Publication type:
- Article